Compare AstraZeneca plc (AZN) vs iShares Global Clean Energy ETF (ICLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs iShares Global Clean Energy ETF — how do they compare? AstraZeneca plc trades at $166.76 (market cap $253.13B), while iShares Global Clean Energy ETF trades at $19.2. The key difference: AstraZeneca plc pays a 1.92% dividend while iShares Global Clean Energy ETF pays none, and iShares Global Clean Energy ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | ICLN | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | — |
52-Week High | $209.48 | $23.75 |
52-Week Low | $137.44 | $13.41 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
ICLN, the iShares Global Clean Energy ETF, trades at $18.625, down 3.25% on the day, with technical indicators showing a bearish trend. The ETF holds 105 global renewable energy companies and has delivered strong year-to-date performance, driven by increased energy demand and policy support. Recent news highlights comparisons with traditional energy and uranium ETFs, emphasizing ICLN's growth focus versus income alternatives.
Outlook remains mixed: clean energy benefits from structural trends like AI-driven power demand and global decarbonization goals, but risks include regulatory uncertainty and high volatility. The ETF's valuation and growth potential appeal to long-term investors, though near-term price action suggests caution amid bearish technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →
